Why Is Novocure Stock Trading Higher On Wednesday? - NovoCure (NASDAQ:NVCR)

Novocure's Phase 3 METIS trial results: TTFields therapy, combined with supportive care, significantly prolongs time to intracranial progression for NSCLC brain metastases patients compared to supportive care alone

Related Keywords

,Novocure Ltd ,Treating Fields ,Premarket Approval ,